Research Article
Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate
Table 2
Baseline characteristics of patients with and without primary composite endpoint.
| | | No primary endpoint () | With primary endpoint () | value |
| | Age, years | | | 0.29 | | Hypertension, (%) | 244 (35.6) | 32 (53.5) | <0.01* | | Hypercholesterolemia, (%) | 75 (10.9) | 4 (6.7) | 0.39 | | Cigarette smoker, (%) | 257 (37.5) | 27 (45.0) | 0.25 | | Lung disease, (%) | 24 (3.5) | 2 (3.3) | 1.00 | | Carcinoma of prostate | | | | | PSA at diagnosis, ng/mL | | | 0.07 | | Gleason score | | | 0.20 | | 2–5, (%) | 34 (5.0) | 6 (10.0) | | | 6–8, (%) | 444 (64.8) | 37 (61.7) | | | 9-10, (%) | 133 (19.4) | 8 (13.3) | | | Not specified, (%) | 74 (10.8) | 9 (15.0) | | | Treatment | | | | | Local treatment, (%) | 452 (66.0) | 34 (56.7) | 0.15 | | ADT, (%) | 466 (68.0) | 51 (85.0) | <0.01* | | Surgical ADT only, (%) | 113 (16.5) | 15 (25.0) | | | Medical ADT only, (%) | 224 (32.7) | 28 (46.7) | | | Medical and Surgical ADT, (%) | 129 (18.8) | 8 (13.3) | |
|
|
(comparison between patients with and without ADT.
ADT: androgen deprivation therapy; PSA: prostate specific antigen.
|
